MENU

Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases

Casas, CG; Catala, A; Hernandez, GC; Rodriguez-Jimenez, P; Fernandez-Nieto, D; Lario, ARV; Fernandez, IN; Ruiz-Villaverde, R; Falkenhain-Lopez, D; Velasco, ML; Garcia-Gavin, J; Baniandres, O; Gonzalez-Cruz, C; Morillas-Lahuerta, V; Cubiro, X; Nart, IF; Se

BRITISH JOURNAL OF DERMATOLOGY
2020
VL / 183 - BP / 71 - EP / 77
abstract
Background The cutaneous manifestations of COVID-19 disease are poorly characterized. Objectives To describe the cutaneous manifestations of COVID-19 disease and to relate them to other clinical findings. Methods We carried out a nationwide case collection survey of images and clinical data. Using a consensus we described five dinical patterns. We later described the association of these patterns with patient demographics, the timing in relation to symptoms of the disease, the severity and the prognosis. Results The lesions may be classified as acral areas of erythema with vesicles or pustules (pseudo-chilblain) (19%), other vesicular eruptions (9%), urticarial lesions (19%), maculopapular eruptions (47%) and livedo or necrosis (6%). Vesicular eruptions appear early in the course of the disease (15% before other symptoms). The pseudo-chilblain pattern frequently appears late in the evolution of the COVID-19 disease (59% after other symptoms), while the rest tend to appear with other symptoms of COVID-19. The severity of COVID-19 shows a gradient from less severe disease in acral lesions to more severe in the latter groups. The results are similar for confirmed and suspected cases, in terms of both dinical and epidemiological findings. Alternative diagnoses are discussed but seem unlikely for the most specific patterns (pseudo-chilblain and vesicular). Conclusions We provide a description of the cutaneous manifestations associated with COVID-19 infection. These may help clinicians approach patients with the disease and recognize cases presenting with few symptoms.
29th Global

AccesS level

Green Published, Bronze

Mentions data

PAPER MENTIONS
Clinical Medicine
  •   Twitter
  • 1.5K
  •   Wikipedia
  • 0
  •   News
  • 154
  •   Policy
  • 0
Global Ranking
  •   Twitter
  • 1.5K
  •   Wikipedia
  • 0
  •   News
  • 154
  •   Policy
  • 0

Mentions Chart

Influratio by dimension
  • Twitter
  • Wikipedia
  • News
  • Policy
PAPER MENTIONS
  •   Twitter
  • 1.5K
  •   Wikipedia
  • 0
  •   News
  • 154
  •   Policy
  • 0
PROYECTO FINANCIADO POR PLAN NACIONAL DE INVESTIGACIÓN AGENCIA ESTATAL DE INVESTIGACIÓN, MINISTERIO DE CIENCIA E INNOVACIÓN. PID2019-109127RB-I00